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Abstract The battle against cancer has advanced tremendously in the last thirty years and the survival rate
	 has	doubled.	However,	it	is	still	difficult	to	achieve	a	generalized	cure.	The	challenge	is	that	cancer	
is	not	a	unique	disease;	it	is	about	dozens	of	different	manifestations,	even	within	the	same	tumor	location.	For	
systems	biology,	each	solid	tumor	 is	a	unique	system	characterized	by	its	cellular	heterogeneity,	 its	 interaction	
with the microenvironment in which it grows and develops, and its ability to adapt and modify it. Recent advances 




analytical tools and trained personnel for the analysis, integration and transfer of the information to physicians. 
This	presentation	describes	 the	concepts	of	personalized	medicine,	Big	Data,	 the	main	advances	 in	genomics	
and bioinformatics as well as their future perspectives and challenges.
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Although	the	fight	against	cancer	has	advanced	tre-
mendously in the last thirty years and the survival rate 
has	doubled,	the	search	for	a	definitive	cure	remains	a	
utopia. The challenge lies in that cancer is not a unique 
disease but many different manifestations, even within the 
tumor itself. For systems biology, each tumor constitutes 
a	system	characterized	by	its	cellular	heterogeneity,	the	
microenvironment	(surrounding	tissue,	immune	system)	in	
which it grows, and its ability to adapt and modify it1. That 
is, a tumor is a unique and variable entity, product of the 
multiple mutations and epigenetic alterations that occur 
in some of the thousands of cells in the early stages of 
malignant transformation. Since these cells can acquire 
new mutations and new genetic variations as the tumor 
grows	and	develops,	an	almost	infinite	amount	of	genomic	
variations can be generated2.
For this reason, cancer treatment becomes a complex 
task, in which oncologists face a mobile and unpredictable 
target. Unfortunately, there is no single solution for all 
cases. While surgery, radiation, and chemotherapy remain 
the primary treatments against cancer, the advances in 
the molecular mechanisms underlying tumor growth are 
generating new approaches to the diagnosis and treat-
ment of the disease.
In	the	last	five	years,	many	new	cancer	treatments	have	
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cancers. From the genetic edition to immunotherapy, the 
future	of	cancer	treatment	focuses	on	finding	a	special-




The paradigm of precision medicine is not new; recent 
advances in genomics and bioinformatics have helped to 
materialize	this	discipline	(Fig.	1).	Personalized	medicine	
has	shown	benefits	for	patients,	allowing	the	oncologists	
to prescribe the most appropriate treatment from an early 
stage	of	care,	minimizing	the	risk	of	adverse	reactions	to	the	
medication, or the lack of effect4.	The	personalized	medicine	
increases	the	overall	efficiency	of	health	care	because	the	
molecular	diagnostic	profiles	can	rule	out	treatments	that	will	
not be effective –avoiding the costs involved– and identify 
those with the highest chance of success.
How are genetic changes identified in tumors?
Precision medicine is a medical model that proposes the 
customization	of	healthcare	 through	medical	decisions,	




habits),	and	 the	genetic	background	of	 the	patient.	The	 interaction	bet-
ween these factors determines that each individual responds differentially 
to	 a	 specific	 treatment.	 In	 oncological	 terms,	 patients	 can	 be	 stratified	
according	to	the	tumor	molecular	profile	allowing	a	more	accurate	diag-
nosis or the selection of the most appropriate treatment
E2: estradiol; Pg: progesterone; BPA: bisphenol A
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individual patient4. This strategy requires to determine 
the molecular mechanisms by which a tumor proliferate, 
escape from the immune system control and resist to the 
potential applied treatment.
The technological-analytical, computational, and 
bioinformatics developments experienced during the 
last decade have allowed moving this model from the 
conceptual to the pragmatic scenario. For example, the 
current	Next	Generation	Sequencing	platforms	 (NGS),	
allow the epigenomics, genomics, and transcriptomics 
characterization	 of	 a	 specific	 tumor.	 Initially,	DNA	and	
RNA are obtained from tissue tumor biopsies, or liquid 
biopsies	(circulating	cell-free	DNA	or	RNA	derived	from	
tumor	exosomes).	Quality	controls	are	 then	carried	out	
to determine the integrity and concentration of nucleic 
acids.	DNA/RNA	samples	are	subjets	to	specific	library	
construction protocols according to the user needs [e.g., 
whole	genome	sequencing	(WGSeq),	whole	exome	se-
quencing	(WESeq),	TargetedSeq,	MethylSeq,	RNAseq,	
small RNAseq] and the sequencing platform employed 
(Illumina:	MySeq,	HiSeq,	and	NovaSeq	series;	Thermo-
Fisher:	PGM,	Ion	Proton,	Ion	S5	series,	etc.)4. The raw 
data	 (FASTQ	files)	 are	 pre-processed	 (demultiplexing,	
quality	control,	adapter	trimming)	and	subject	to	a	specific	
pipeline for the extraction of non-trivial information such as 
the detection of activated/deactivated signaling pathways 
or	the	identification	of	clinically	actionable	variants	(Fig.	2).	
In this sense, the NGS platform generates a complex 
corpus of data that makes genomic and bioinformatics fall 
within the disciplines that require Big Data approaches5. 
Although technological progress has made NGS studies 
increasingly accessible in terms of availability and costs, 
the current bottleneck lies in the ability to handle the large 
volume of data generated. 
There are more than 3 million base pairs in the 
human	 exome,	 distributed	 in	 180,000	 exons	 (25,000	
coding	genes)2. The complete exome or transcriptome 
sequencing	for	a	small	project	(10	to	30	samples)	gener-
ates	terabytes	of	raw	data	(FASTQ	files).	These	data	are	
pre-processed and aligned against a reference genome 
Fig.	2.–	Bioinformatics	workflows	 for	NGS	(Next	Generation	Sequencing)	
data	analysis	(Exome-Seq	in	the	left	and	RNA-seq	in	the	right)
FASTQ: TXT file with the reads sequence and quality; BAM: binary alig-
nment map; SNV: single nucleotide variants; INDEL: insertion or deletion 
variants
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(BAM	files	for	binary	version	of	sequence	alignment)	that	
are usually on the gigabyte scale depending on the se-
quencing	coverage	(average	number	of	unique	reads	that	
include	a	given	nucleotide	in	the	reconstructed	sequence)	
and the length of reads5.
The initial steps of pre-processing and alignment are 
the most demanding in terms of computational capability, 
and the downstream bioinformatics processes depend on 
the type of study to be performed, requiring less informat-
ics resources. Various public consortiums and companies 
are developing cloud-based bioinformatics platforms to 
facilitate	 the	 implementation	 of	 the	 required	workflows	
with on-demand computational capability. 
Collective bioinformatics intelligence
The	 term	 “bioinformatics”	 is	 now	 recognized	as	a	 field	
that encompasses biology, medicine, computer science, 
mathematics, statistics, and information technology. 
Bioinformatics tools and databases constitute an integral 
component of the current research process in biomedical 
sciences6. Since the introduction of information technology 
in biological research, a plethora of computational tools 
and databases have emerged, contributing to break-
throughs	in	the	field.	The	emergence	of	NGS	technolo-
gies has inspired the development of new computational 
techniques, and also required the implementation of highly 
sophisticated pipelines.
In the past decade, the notion of ‘biological data’ has 
changed in magnitude and complexity from sets of hun-
dreds	to	sets	of	millions	of	entities	(e.g.,	genes,	alterna-
tive	splicing	variants,	protein,	isoforms,	CpG	island).	This	
exponential increase in the volume of biological data has 
stimulated the development of an ever-increasing number 
of bioinformatics tools6. As there is no just a single cure 
for	cancer,	there	is	no	a	single	tool	to	analyze	the	data.	
As soon as new tools and techniques are developed, new 
data sources arise, demanding radical improvements 
in the algorithms for processing and analysis. No less 
relevant is the lack of standards regarding how genomic 
data is collected, stored, and processed, which raises 
evident problems in terms of reproducibility5. In this sense, 






repository that enables data sharing across cancer ge-
nomic	studies	(TCGA,	TARGET,	CGCI,	etc.)	in	support	of	
precision medicine7. On the other hand, the Bioconductor 
(https://www.bioconductor.org/)8,	Biocontainers	 (https://
biocontainers.pro/)9,	and	Galaxy	(https://usegalaxy.org/)10 
projects provide open-source bioinformatics tools allowing 
the reproducible implementation of data analytics tools 
and pipelines. In addition, the DREAM challenge is a 
public/private effort that appeals to the collaborative and 
transparent data exchange to evaluate existing analytical 
tools, suggest improvements, and develop new solutions 
(http://dreamchallenges.org/).
Challenges of implementing precision 
medicine
 
The current public and private health systems are im-
mersed	 in	 a	 sea	 of	 data:	medical	 records,	 results	 of	
clinical trials, biometric data monitoring, diverse diagnostic 
images, and genetic information of patients. But more 
importantly, the exploding volume and speed of unstruc-
tured data growth cannot be appropriately managed with 
traditional database systems. Volume, variety, and veloci-
ty	are	precisely	 the	variables	 that	characterize	any	Big	
Data environment5. Precision medicine is a discipline in 
constant evolution due to the dynamism of technological 
advances and the continuous development of new analyti-
cal tools. Like any technological advent, its incorporation 
by	the	scientific	community	implies	an	adaptation	period,	
which is even longer for its implementation in the health 
system. Technical and human resources are two relevant 
components to support precision medicine implementa-
tion. Additionally, the institutional and idiosyncratic legal 
barriers make the clinical genomics set up a challenge for 
its consolidation in the health system.
Technological and human resources
 
The technology associated with the management of Big 
Data is already a consummate reality. The fundamental 
pillars	are	the	systems	of	file	distribution,	the	scalable	data-
bases,	the	mass	processing	software	(Hadoop	type),	cloud	
computing, and the Internet5. This technology, however, 
still needs to be consolidated in the health system, being 
necessary to increase the public and private investments 
for these types of approaches. One of the fundamental 
aspects	 lies	 in	 the	human	 resources:	 trained	scientists	
and technicians for data analysis and interpretation. They 
constitute the link between the analysis and interpreta-
tion of the data and the transfer of the information to the 
physicians so that they make the appropriate decisions 
about their patients. 
Security of genomic data
 
Genomic data need to be protected. Therefore, its privacy 
and	confidentiality	should	be	preserved	similarly	to	other	
protected health information. Privacy safeguards include 
the	 utilization	of	 data	 encryption,	 password	protection,	
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secure data transmission, auditions of data transferring 
methods, and the operation of institutional strategies 
against data breaches and mischievous abuse of the 
data11.	The	Fair	Information	Practices	Principles	(FIPPs)	
offer a framework for enabling data sharing and usage 
based on the guidelines adopted by the U.S. Department 
of Health and Human Services12.
Current status and perspectives
 
Genomics and bioinformatics are two fundamental pillars 
in	the	development	and	implementation	of	personalized	
precision medicine in oncology. These technologies and 
analytical tools need to be implemented in an integrated 
way with the information available in the electronic medi-
cal records facilitating the physician interpretation. This 
must be achieved in the strictest framework of ethical and 
security safeguards since personal information is highly 
sensitive, and is under legal protection requiring the col-
laboration of all health system actors.
Genomics and bioinformatics-based approaches will 
allow	the	identification	of	the	most	effective	treatment	for	
each patient reducing the chances of treatment failure. 
For example, colorectal cancer can be considered to 
include	many	distinct	molecular	diseases,	characterized	
by	a	partially	defined	pattern	of	molecular	changes	that	
affect various molecular pathways. This diversity of tumors 
has challenged the therapies developed during the past 
years, leading to the need to recruit patient groups with 
similar molecular alterations, which can be addressed 
with	more	personalized	therapies.	An	increasing	number	
of clinical trials have focused on the use of new drugs 
directed	against	specific	pathways	to	be	used	alone	or	in	
combination.	The	correct	stratification	of	patients	and	the	
appropriate choice of therapeutic agents will eventually 
lead	to	significant	advances	in	the	treatment	of	colorectal	
cancer and cancer in general13.
In addition to inter-tumor diversity, the intra-tumor het-
erogeneity	brings	even	more	challenges	to	the	field.	The	
coexistence of multiple cellular subclones with different 
sets of molecular changes and different drug sensitivities 
implies that therapeutic strategies directed against the 
predominant aberrations may not be effective against the 
whole tumor14. The single-cell RNA sequencing approach 
is one of the recent advances in genomics that is generat-
ing a new corpus of complex data. This data will need to 
be	analyzed	to	discover	new	entities	within	the	same	tumor	
and thus adjust the accuracy of the therapies. Although 
the	first	advances	are	already	being	seen,	especially	in	
the diagnosis and treatment of cancer, much remains to 
be	done	to	reach	a	truly	personalized	precision	medicine.
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